Arvinas Finds First Partner For Protein-Degradation Technology In Merck
This article was originally published in The Pink Sheet Daily
Executive Summary
Arvinas’ proprietary work has been in oncology, with a prostate cancer candidate slated to enter the clinic in 2016, but the collaboration with Merck will focus on a variety of targets and therapeutic areas.